Your browser doesn't support javascript.
loading
Synergistic impact of Gui Zhi Shao Yao Zhi Mu Decoction and leflunomide on gut microbiota in rheumatoid arthritis: insights from 16S rDNA sequencing.
Sun, Ying; Chen, Xiaoheng; Zhang, Ye; Chen, Xiaojun; Zhang, Chen; Zhao, Jing; Sun, Songge; Zhang, Yanzhen; Qiu, Xinping.
Afiliación
  • Sun Y; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Chen X; Thyroid Diseases Department, Dongzhimen Hopital Beijing University of Chinese Medicine Dongcheng, Beijing 100700, China.
  • Zhang Y; School of Medicine and Health, Jiuzhou Polytechnic Xuzhou 221113, Jiangsu, China.
  • Chen X; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Zhang C; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Zhao J; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Sun S; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Zhang Y; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
  • Qiu X; Rheumatology Department, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital Shunyi, Beijing 101300, China.
Am J Transl Res ; 16(2): 654-668, 2024.
Article en En | MEDLINE | ID: mdl-38463585
ABSTRACT

BACKGROUND:

Rheumatoid arthritis (RA) is a chronic autoimmune disease with complex pathogenesis, including alterations in the gut microbiota. Gui Zhi Shao Yao Zhi Mu Decoction (GSZD), a traditional Chinese herbal formula, has shown efficacy in RA treatment, but its impact on intestinal microflora remains unclear. This study aimed to investigate the effects of GSZD combined with leflunomide on the gut microbiota of RA patients.

METHODS:

The study enrolled 48 RA patients who were randomly assigned to either a control group receiving leflunomide or a treatment group receiving GSZD combined with leflunomide for 12 weeks. Gut microbiota composition was analyzed pre- and post-intervention using 16S rDNA sequencing. Changes in microbial diversity, abundance, and metabolic functions were assessed.

RESULTS:

Post-treatment, both groups exhibited significant alterations in gut microbiota composition. GSZD combined with leflunomide led to an increased Bacteroidetes/Firmicutes ratio and a reduction in Actinobacteria compared to leflunomide alone. This was associated with beneficial shifts in microbial genera and metabolic pathways, suggesting improved gut health and systemic immune modulation.

CONCLUSION:

GSZD combined with leflunomide significantly modulates the gut microbiota in RA patients. This study provides insights into the mechanisms underlying the therapeutic effects of GSZD and highlights the potential of integrating traditional Chinese medicine with conventional treatments in managing RA.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Transl Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Transl Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos